Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood

Abstract

Allogeneic blood transfusion can result in an immune response against major histocompatibility complex (MHC) antigens, potentially complicating future transfusions or transplants. We previously demonstrated that pathogen reduction of platelet‐rich plasma (PRP) with riboflavin and ultraviolet light (UV+R) can prevent alloimmunization in mice. A similar pathogen‐reduction treatment is currently under development for the treatment of whole blood using riboflavin and a higher dose of UV light. We sought to determine the effectiveness of this treatment in the prevention of alloimmunization.

Document Details

Document Type
Pub Defense Publication
Publication Date
Nov 18, 2016
Source ID
10.1111/trf.13895

Entities

People

  • Heather Inglis
  • John W. Heitman
  • Marcus O. Muench
  • Philip J Norris
  • Rachael P. Jackman
  • Raymond P Goodrich
  • Susanne Marschner

Organizations

  • Blood Systems Research Institute
  • National Heart, Lung, and Blood Institute
  • United States Department of Defense
  • University of California, San Francisco

Tags

Fields of Study

  • Medicine

Readers

  • Immunology
  • Trauma Surgery or Emergency Medicine.

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech